Kancera develops drugs that counteract damage from acute and chronic inflammation.

Fraktalkine blocker KAND567 is developed primarily to effectively counteract hyperinflammation in various medical conditions and thus protect vital organs, e.g. in connection with heart attacks and severe viral infections.

ABOUT US

Kancera develops drugs that counteract damage from acute and chronic inflammation. Fraktalkine blocker KAND567 is developed primarily to effectively counteract hyperinflammation in various medical conditions and thus protect vital organs, e.g. in connection with heart attacks and severe viral infections.

RESEARCH & DEVELOPMENT

Kancera has five drug projects in the portfolio. Kancera’s main resources are invested in the two Fractalkine projects. The further development of the HDAC project is externally financed through agreement with the pharmaceutical company Grünenthal. The PFKFB3 project is funded through an EU Horizon2020 project and ROR1 mainly through academic collaborations.

INVESTOR RELATIONS

Kancera’s share was linked into the NASDAQ OMX First North on February 25, 2011. Here, you will find information about the share as well as the option to download a prospectus, annual reports, and other reports.

Press releases

Calendar

21 aug: Interim report januari-juni 2020

20 nov: Interim report januari-september 2020